Only a quick few points from me as not much time.
$598 = margins of $373. As such $970 spod prices is double margins and $785 is about 1.5x margins.
That gives annual EBITDA of somewhere between A$570-760m a year based on current price range (even allowing some pullback over the next couple of years).
Timeline aimed for completion end of 2019 - call it start of 2020 which is quite good.
Ganfeng and Greatwall commitments cover around 70% of capital needs. We have 200Kt unsigned and cashflow to pay for the rest.
Looks good to me.
- Forums
- ASX - By Stock
- PLS
- Ann: Outstanding PFS Results 5Mtpa Expansion
Ann: Outstanding PFS Results 5Mtpa Expansion, page-4
-
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PLS (ASX) to my watchlist
(20min delay)
|
|||||
Last
$3.02 |
Change
-0.040(1.31%) |
Mkt cap ! $9.090B |
Open | High | Low | Value | Volume |
$3.08 | $3.11 | $3.02 | $55.82M | 18.22M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
37 | 424619 | $3.02 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$3.03 | 17344 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
35 | 329137 | 3.020 |
23 | 502241 | 3.010 |
92 | 359053 | 3.000 |
16 | 98735 | 2.990 |
19 | 101042 | 2.980 |
Price($) | Vol. | No. |
---|---|---|
3.040 | 32598 | 6 |
3.050 | 109743 | 7 |
3.060 | 104622 | 7 |
3.070 | 137237 | 8 |
3.080 | 1849 | 2 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
PLS (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online